Compare · RECT vs TMO
RECT vs TMO
Side-by-side comparison of Rectitude Holdings Ltd (RECT) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- RECT operates in Consumer Discretionary, while TMO operates in Industrials - the two are in different parts of the market.
- TMO is the larger of the two at $257.53B, about 13737.2x RECT ($18.7M).
- TMO has hit the wire 7 times in the past 4 weeks while RECT has been quiet.
- TMO has more recent analyst coverage (25 ratings vs 0 for RECT).
- Company
- Rectitude Holdings Ltd
- Thermo Fisher Scientific Inc
- Price
- $1.21-3.59%
- $690.13-0.92%
- Market cap
- $18.7M
- $257.53B
- 1M return
- -10.37%
- -
- 1Y return
- -64.41%
- -
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- News (4w)
- 0
- 7
- Recent ratings
- 0
- 25
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest RECT
- SEC Form 6-K filed by Rectitude Holdings Ltd
- SEC Form 6-K filed by Rectitude Holdings Ltd
- Rectitude Holdings Ltd Declares Cash Dividend of $0.10 per Ordinary Share
- Rectitude Holdings Ltd Announces Full-Year Financial Results for the Fiscal Year Ended March 31, 2026
- SEC Form 20-F filed by Rectitude Holdings Ltd
- Director Huang Dong was granted 17,000 units of ORDINARY SHARES OF RECTITUDE HOLDINGS LTD., increasing direct ownership by 3% to 517,000 units (SEC Form 4)
- Director Ang Siew Sang was granted 14,000 units of ORDINARY SHARES OF RECTITUDE HOLDINGS LTD. (SEC Form 4)
- Director Aw Victor was granted 11,000 units of ORDINARY SHARES OF RECTITUDE HOLDINGS LTD. (SEC Form 4)
- CHIEF FINANCIAL OFFICER Chan Kah Chun was granted 10,000 units of ORDINARY SHARES OF RECTITUDE HOLDINGS LTD. (SEC Form 4)
- Rectitude Holdings Ltd Secures Additional AIMS System Orders for Major Infrastructure and Residential Projects Across Singapore
Latest TMO
- SEC Form 4 filed by Director Weisler Dion J
- SEC Form 4 filed by Director Sperling Scott M
- SEC Form 4 filed by Director Lynch Karen S
- SEC Form 4 filed by Director Johnson Jennifer M
- SEC Form 4 filed by Director Keith R. Alexandra
- Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, October 21, 2026
- Thermo Fisher Scientific Launches Gibco™ CHO-K1 Catalog Panel Media and Feed to Accelerate Biologics Development
- Thermo Fisher upgraded by UBS with a new price target
- CLSA initiated coverage on Thermo Fisher with a new price target
- Executive Vice President Shafer Michael D covered exercise/tax liability with 790 shares, decreasing direct ownership by 4% to 20,204 units (SEC Form 4)